These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 12674326

  • 21. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods].
    Meddah B, Brazier M, Kamel S, Maamer M, Samson L, Desmet G, Sebert JL.
    Ann Biol Clin (Paris); 1996; 54(10-11):353-8. PubMed ID: 9092303
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P, Alvarez L, Monegal A, Guañabens N, Durán M, Echevarría M, Ros I, Ballesta AM, Muñoz-Gómez J.
    J Bone Miner Metab; 2002 Mar; 20(2):116-20. PubMed ID: 11862534
    [Abstract] [Full Text] [Related]

  • 28. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
    Cremers SC, Eekhoff ME, Den Hartigh J, Hamdy NA, Vermeij P, Papapoulos SE.
    J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation.
    Rosano TG, Peaston RT, Bone HG, Woitge HW, Francis RM, Seibel MJ.
    Clin Chem; 1998 Oct; 44(10):2126-32. PubMed ID: 9761245
    [Abstract] [Full Text] [Related]

  • 35. Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women.
    Tobias JH, Laversuch CV, Wilson N, Robins SP.
    Calcif Tissue Int; 1996 Nov; 59(5):407-9. PubMed ID: 8849410
    [Abstract] [Full Text] [Related]

  • 36. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
    Hamdy NA, Papapoulos SE, Colwell A, Eastell R, Russell RG.
    Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Markers of bone resorption in patients treated with pamidronate.
    Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R.
    Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.